Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy-Reference-Cited by-同舟云学术

Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy

Published:2024-02-10 Issue:7 Volume:130 Page:1109-1118
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ye Hai-Shan,Zhou Dan,Li Hong,Lv Jin,Huang Hui-Qi,She Jia-Jun,Nie Jun-Hua,Li Ting-Ting,Lu Meng-Di,Du Bo-Le,Yang Shu-Qing,Chen Pei-Xian,Li Sheng,Ye Guo-Lin^ORCID,Luo Wei^ORCID,Liu Jia^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02595-w.pdf

Reference49 articles.

1. Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7.

2. Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:61–71.

3. Spring LM, Bar Y, Isakoff SJ. The evolving role of neoadjuvant therapy for operable breast cancer. J Natl Compr Canc Netw. 2022;20:723–34.

4. Derouane F, van Marcke C, Berliere M, Gerday A, Fellah L, Leconte I, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers (Basel). 2022;14:3876.

5. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.